Trade-offs Between Efficacy and Cardiac Toxicity of Adjuvant Chemotherapy in Early-Stage Breast Cancer Patients: Do Competing Risks Matter?

Breast Journal

Volumn 23, Issue 4, 2017, Pages 401-409

  Alarid Escudero, Fernando ^a   Blaes, Anne H ^b   Kuntz, Karen M ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

adjuvant chemotherapy; breast cancer; cardiac toxicity; decision analytic model; Markov model

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CARDIOTOXICITY; CAUSE OF DEATH; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; EARLY CANCER; FEMALE; HIGH RISK POPULATION; HUMAN; INTERMEDIATE RISK POPULATION; LIFE YEARS; LOW RISK POPULATION; META ANALYSIS (TOPIC); METASTASIS; MORTALITY RISK; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RECURRENCE RISK; RISK BENEFIT ANALYSIS; SIMULATION; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DECISION SUPPORT SYSTEM; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK FACTOR; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARDIOTOXICITY; CHEMOTHERAPY, ADJUVANT; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS;

EID: 85022229974     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12757     Document Type: Article

References (49)

1. Early Breast Cancer Trialists Collaborative Group (EBCTCG), Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432–44.
2. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–717.
3. Towns K, Bedard PL, Verma S. Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer. Curr Oncol 2008;15(Suppl 1):S16–29.
4. Ewer MS, Ewer SM. Long-term cardiac safety of dose-dense anthracycline therapy cannot be predicted from early ejection fraction data. J Clin Oncol 2009;27:6073–5.
5. Ewer MS, Von Hoff DD, Benjamin RS. A historical perspective of anthracycline cardiotoxicity. Heart Fail Clin 2011;7:363–72.
6. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-lnduced congestive heart failure. Ann Intern Med 1979;91:710–7.
7. Bird BRJH, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008;14:14–24.
8. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50:1435–41.
9. Azim HA, de Azambuja E, Colozza M, Bines J, Piccart MJ. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol 2011;22:1939–47.
10. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press, 1996:456 p.
11. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007;25:3808–15.
12. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–26.
13. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res BCR 2006;8:R25.
14. Cronin M, Sangli C, Liu M-L, et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 2007;53:1084–91.
15. Slodkowska EA, Ross JS. MammaPrint 70-gene signature: another milestone in personalized medi- cal care for breast cancer patients. Expert Rev Mol Diagn 2009;9:417–22.
16. Albain KS, Paik S, van't Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. The Breast 2009;18(Suppl 3):S141–5.
17. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55–65.
18. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980–91.
19. Gribbin J, Dewis R. Adjuvant ! Online: Review of Evidence Concerning its Validity, and Other Considerations Relating to its use in the NHS. Early and Locally Advanced Breast Cancer: Diagnosis and Treatment. Cardiff, UK: National Collaborating Centre for Cancer, 2009:1–12.
20. National Institute for Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. London: NICE, 2013:93 p.
21. Weinstein MC, Fineberg HV. Clinical Decision Analysis, 1st ed. Philadelphia, PA: Elsevier Health Sciences, 1980:351 p.
22. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322–38.
23. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983;3:419–58.
24. TreeAge Software. TreeAge Pro 2014. Williamstown, MA: TreeAge Software, Inc., 2014.
25. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2015.
26. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer, 2009:212 p.
27. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530–6.
28. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790–800.
29. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726–34.
30. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869–79.
31. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review 1975-2010. Bethesda, MD: National Cancer Institute, 2013.
32. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107–15.
33. Arias E. United States life tables, 2009. Natl Vital Stat Reports 2014;62:13–14.
34. Kuntz KM, Weinstein MC. Life expectancy biases in clinical decision modeling. Med Decis Making 1995;15:158–69.
35. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000;18:3302–17.
36. Alehagen U, Rahmqvist M, Paulsson T, Levin L-A. Quality-adjusted life year weights among elderly patients with heart failure. Eur J Heart Fail 2008;10:1033–9.
37. Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Making 2012;32:722–32.
38. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381–7.
39. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27:1177–83.
40. The New York Times. Chemotherapy. Breast Cancer In-Depth Report, 2014:14–6.
41. Gianni L, Valagussa P. Anthracyclines and early breast cancer: the end of an era? J Clin Oncol 2009;27:1155–7.
42. Crozier JA, Swaika A, Moreno-Aspitia A. Adjuvant chemotherapy in breast cancer: to use or not to use, the anthracyclines. World J Clin Oncol 2014;5:529–38.
43. Mann TA. The Cost-Effectiveness of Cardiac Monitoring in Breast Cancer Patients Who Have Received Cardiotoxic Therapies. Austin: The University of Texas, 2012.
44. Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 2015;373:2005–14.
45. European Organisation for Research and Treatment of Cancer—EORTC. Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes (MINDACT). ClinicaltrialsGov. Bethesda, MD: National Library of Medicine (US), 2006.
46. Hall PS, McCabe C, Stein RC, Cameron D. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J Natl Cancer Inst 2012;104:56–66.
47. Hillner BE, Smith TJ. Efficacy and cost efectivenes of adjuvant chemotherapy in women with node-negative breast cancer: a decision-analysis model. N Engl J Med 1991;324:160–8.
48. Hillner BE, Smith TJ, Desch CE. Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model. Breast Cancer Res Treat 1993;25:97–105.
49. Hillner BE, Smith TJ. Should women with node-negative breast cancer receive adjuvant chemotherapy?–Insights from a decision analysis model. Breast Cancer Res Treat 1992;23:17–27.